Suven Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 13 Feb 2025
Result Summary
- Suven Pharmaceuticals Ltd reported a 18.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 37.9%.
- Its expenses for the quarter were up by 23.7% QoQ and 26.3% YoY.
- The net profit increased 1.6% QoQ and increased 78.2% YoY.
- The earnings per share (EPS) of Suven Pharmaceuticals Ltd stood at 3.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 322.86 | 271.84 | 234.16 | 18.8% | 37.9% |
Total Expenses | 213.13 | 172.34 | 168.70 | 23.7% | 26.3% |
Profit Before Tax | 109.73 | 99.50 | 65.47 | 10.3% | 67.6% |
Tax | 26.44 | 17.52 | 18.71 | 50.9% | 41.3% |
Profit After Tax | 83.29 | 81.98 | 46.75 | 1.6% | 78.2% |
Earnings Per Share | 3.20 | 3.20 | 1.80 | 0.0% | 77.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Suven Pharmaceuticals Ltd is primarily engaged in the business of providing pharmaceutical and life sciences solutions. The company operates within the pharmaceutical industry, focusing on the manufacturing and sale of bulk drugs and drug intermediates. Suven Pharmaceuticals is known for its contributions to the development and production of active pharmaceutical ingredients (APIs) and formulations. The company plays a significant role in contract research and manufacturing services (CRAMS), catering to various clients in the global pharmaceutical market. Although specific details about recent major developments are not available in the provided data, Suven Pharmaceuticals continues to be an integral player in its industry sector through its product offerings and services.
Revenue
In Q3FY25, Suven Pharmaceuticals Ltd reported a total income of ₹322.86 crores, marking a growth of 18.8% compared to the previous quarter (Q2FY25) where the total income was ₹271.84 crores. On a year-over-year basis, the total income increased by 37.9% from Q3FY24, when it was ₹234.16 crores. This indicates a strong growth trajectory in revenue generation over both the quarterly and yearly periods. The substantial rise in total income suggests that the company has experienced significant topline growth, potentially driven by increased sales or expansion of its service offerings in the pharmaceutical sector.
Profitability
The profitability metrics for Suven Pharmaceuticals Ltd show positive growth trends in Q3FY25. The company achieved a profit before tax of ₹109.73 crores, reflecting a 10.3% increase from the previous quarter (Q2FY25) and a 67.6% increase from the same quarter in the previous year (Q3FY24). This indicates a robust improvement in profitability on both a quarterly and yearly basis. The profit after tax for Q3FY25 was ₹83.29 crores, representing a modest quarter-over-quarter growth of 1.6% from ₹81.98 crores in Q2FY25 and a significant year-over-year increase of 78.2% from ₹46.75 crores in Q3FY24. The earnings per share remained steady at ₹3.20 in both Q3FY25 and Q2FY25, but showed a notable year-over-year improvement of 77.8% from ₹1.80 in Q3FY24, highlighting the company’s enhanced profitability per share.
Operating Metrics
The total expenses for Suven Pharmaceuticals Ltd in Q3FY25 stood at ₹213.13 crores, which was a 23.7% increase from Q2FY25 where the expenses were ₹172.34 crores. Compared to Q3FY24, total expenses rose by 26.3% from ₹168.70 crores. This increase in expenses could be associated with factors such as higher production costs or investment in operational capabilities. The tax expense for Q3FY25 was ₹26.44 crores, reflecting a significant quarter-over-quarter increase of 50.9% from ₹17.52 crores in Q2FY25, and a year-over-year rise of 41.3% from ₹18.71 crores in Q3FY24. These figures suggest an increase in the effective tax burden, possibly due to higher taxable income. Overall, the financial metrics indicate an expansion in both revenue and costs, illustrating the company’s operational dynamics over the analyzed periods.
